Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration raised no objections to proposed protocol amendments for the ongoing Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small cell lung cancer (NSCLC) adenocarcinoma. The FDA’s written response to the company’s Type C meeting request provides a clearer regulatory path forward, according to the company.
The amendments focus on the EGFR exon 21 L858R-mutant never-smoker population, where emerging data suggest LP-300 may offer differentiated benefit when combined with standard chemotherapy after kinase inhibitor treatment failure. This precision approach could address a significant unmet need in lung cancer, as never-smokers with EGFR mutations often have limited options after targeted therapies stop working.
Lantern Pharma is a clinical-stage precision oncology company that leverages artificial intelligence and its proprietary RADR platform to streamline drug development. The HARMONIC trial is evaluating LP-300, a cisplatin/ethacraplatin analog, in never-smoker patients with relapsed advanced lung adenocarcinoma following tyrosine kinase inhibitor (TKI) treatment. The company’s pipeline also includes LP-184 and LP-284, targeting various cancers.
The FDA’s support marks a key milestone for Lantern, potentially expediting the trial and bringing a new treatment option closer to patients. For the broader oncology field, it underscores the growing role of precision medicine in targeting specific genetic mutations. The decision also highlights the importance of biomarker-driven trials in improving outcomes for niche patient populations.
Lantern Pharma operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The company’s withZeta.ai platform, a multi-agentic AI co-scientist, is now commercially available as a subscription service for the biomedical community, generating a new revenue stream. For more details, visit the full press release at https://ibn.fm/RxklmABOUT.
Investors can access the latest news and updates on Lantern Pharma at https://ibn.fm/LTRNAbout.
